Long-term Oncologic Outcomes of Robotic-assisted Radical Prostatectomy by a Single Surgeon

Abstract

AIM: The aim of the study was to evaluate the long-term oncology outcomes of prostate cancer patients receiving robotic-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: We retrospectively evaluated 111 patients with clinically-localized prostate cancer receiving RARP with a mean follow-up of 103.43 months. RESULTS: The 5-year BCRFS and 8-year BCRFS among low-, intermediate-, and high-risk patients were 95.5% vs. 77.1% vs. 53.7% and 95.5% vs. 61.2% vs. 48.1% (p=0.000). The median time to BCR in these three groups was 122.5, 98.0, and 79.2 months. Regarding postoperative factors, positive lymph node (HR=3.748, 95% CI=1.407-9.984), pathology Gleason score (HR=1.507, 95%CI=1.010-2.248), and postoperative nadir PSA <0.003 ng/ml (HR=0.058, 95%CI=0.020-0.166) were independent risk factors for BCR. CONCLUSION: D'Amico risk classification was effective at predicting biochemical recurrence in patients receiving RARP. Furthermore, postoperative risk factors such as metastatic lymph node, pathology Gleason score, and nadir PSA <0.003 ng/ml were independent predictors of biochemical recurrence.